homepage-top-section

The EC approval enables to use of BLENREP as monotherapy to treat multiple myeloma in adult patients who have secured at least four prior therapies including one proteasome

As part of the deal, Acadia has purchased all of the outstanding shares of CerSci for $52.5m in the form of its stock. CerSci shareholders are also eligible

Forbius is engaged in the designing and development of advanced biotherapeutics to treat cancer and fibrotic diseases. The company has developed a portfolio of selective and potent inhibitors

Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group and its affiliates, has signed an agreement to acquire Takeda’s wholly-owned subsidiary Takeda Consumer Healthcare

The acquisition of Momenta Pharmaceuticals is expected to help the Janssen Pharmaceutical Companies of Johnson & Johnson to grow its position further in immune-mediated diseases and bring in

In October 2018, the companies first announced their collaboration for the discovery, development and commercialisation of advanced targeted immuno-oncology treatments for cancer. As part of the expanded multi-year

As per terms of the deal, Sanofi will purchase all of the outstanding shares of Principia by paying $100 per share in cash. Principia Biopharma is engaged in

Under the deal, Ligand Pharmaceuticals will purchase all outstanding shares of Pfenex for $12 per share in cash or $438m in equity value on a fully diluted basis.

The studies indicated that the Depakine has induced disabilities in about 15,000 to 30,000 children whose mothers took the drug valproate during pregnancy. The drug, which has been